Drug General Information
Drug ID	D08CGU
Former ID	DCL000496
Drug Name	Bevacizumab + Rituximab
Synonyms	Rituxan (TN)
Drug Type	Antibody
Indication	Lymphoma; Non-hodgkin's lymphoma [ICD9: 200, 202, 202.8; ICD10:C81-C86, C82-C85]		Phase 3	[522045]
Company	Roche
Structure		Download 2D MOL 3D MOL
Formula	C14H18ILiN2O3
PubChem Compound ID	24801580
Target and Pathway
Target(s)	B-lymphocyte antigen CD20	Target Info		[551607]
	Vascular endothelial growth factor	Target Info	Inhibitor	[551607]
KEGG Pathway	Hematopoietic cell lineage
References
Ref 522045	ClinicalTrials.gov (NCT00486759) A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health.
Ref 551607	Clinical pipeline report, company report or official report of Roche (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.